CHO PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.2 TWD | -0.36% |
|
+0.91% | -20.35% |
| Mar. 20 | CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,551 | 4,421 | 4,575 | 15,354 | 25,204 | 14,830 |
| Enterprise Value (EV) 1 | 3,471 | 2,658 | 3,087 | 14,063 | 24,171 | 12,228 |
| P/E ratio | -18 x | -12.3 x | -15.4 x | -74.6 x | -74.5 x | -43.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 19,142 x | 14,884 x | 33,149 x | 4,301 x | 420,067 x | - |
| EV / Revenue | 11,970 x | 8,948 x | 22,373 x | 3,939 x | 402,853 x | - |
| EV / EBITDA | -12.1 x | -7.82 x | -10.9 x | -76.1 x | -74.4 x | -48.9 x |
| EV / FCF | -24.6 x | -17.6 x | -18.3 x | -109 x | -172 x | -59.3 x |
| FCF Yield | -4.07% | -5.68% | -5.45% | -0.92% | -0.58% | -1.69% |
| Price to Book | 2.13 x | 1.95 x | 2.33 x | 8.81 x | 17.6 x | 4.98 x |
| Nbr of stocks (in thousands) | 182,005 | 183,424 | 183,716 | 183,886 | 183,971 | 214,001 |
| Reference price 2 | 30.50 | 24.10 | 24.90 | 83.50 | 137.0 | 69.30 |
| Announcement Date | 3/13/19 | 3/27/20 | 2/25/22 | 2/25/22 | 3/25/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.29 | 0.297 | 0.138 | 3.57 | 0.06 | - |
| EBITDA 1 | -286.6 | -339.9 | -282 | -184.9 | -324.7 | -250.3 |
| EBIT 1 | -319.2 | -369.2 | -309.6 | -210.5 | -350.9 | -269 |
| Operating Margin | -110,080.34% | -124,297.31% | -224,315.94% | -5,896.11% | -584,833.33% | - |
| Earnings before Tax (EBT) 1 | -306.6 | -358.4 | -296.8 | -205.9 | -338.4 | -306.1 |
| Net income 1 | -306.6 | -358.4 | -296.8 | -205.9 | -338.4 | -306.1 |
| Net margin | -105,713.45% | -120,663.97% | -215,100.72% | -5,768.21% | -563,988.33% | - |
| EPS 2 | -1.690 | -1.960 | -1.620 | -1.120 | -1.840 | -1.600 |
| Free Cash Flow 1 | -141.3 | -150.9 | -168.3 | -129 | -140.3 | -206.1 |
| FCF margin | -48,733.32% | -50,804.88% | -121,929.62% | -3,612.43% | -233,894.38% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/13/19 | 3/27/20 | 2/25/22 | 2/25/22 | 3/25/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2,080 | 1,763 | 1,487 | 1,291 | 1,033 | 2,603 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -141 | -151 | -168 | -129 | -140 | -206 |
| ROE (net income / shareholders' equity) | -11.1% | -14.7% | -14% | -11.1% | -21.3% | -13.9% |
| ROA (Net income/ Total Assets) | -7.13% | -9.05% | -8.47% | -6.52% | -12.5% | -7.17% |
| Assets 1 | 4,300 | 3,958 | 3,504 | 3,159 | 2,697 | 4,268 |
| Book Value Per Share 2 | 14.30 | 12.30 | 10.70 | 9.480 | 7.760 | 13.90 |
| Cash Flow per Share 2 | 8.460 | 6.890 | 5.370 | 4.230 | 2.750 | 0.9500 |
| Capex 1 | 2.84 | 11.4 | 19.2 | 2.64 | 9.4 | 2 |
| Capex / Sales | 977.59% | 3,850.51% | 13,884.06% | 73.98% | 15,661.67% | - |
| Announcement Date | 3/13/19 | 3/27/20 | 2/25/22 | 2/25/22 | 3/25/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.35% | 362M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6586 Stock
- Financials CHO Pharma, Inc.
